Drug-induced systemic lupus erythematosus associated with etanercept therapy. Export

@article{citeulike:3022000, abstract = {Specific antagonists of tumour necrosis factor (TNF)-alpha have rapidly gained popularity for the treatment of rheumatoid arthritis. The monoclonal antibody against TNF-alpha, infliximab, has been associated with induction of systemic lupus erythematosus (SLE); however, there have been no published reports of drug-induced SLE associated with the soluble TNF-alpha receptor etanercept. We describe four female patients who developed signs and symptoms of SLE during treatment with etanercept; in two SLE was unambiguous. On diagnosis of SLE, etanercept was discontinued and the SLE-related symptoms promptly resolved. Etanercept should be considered in the list of agents associated with drug-induced SLE.}, author = {Shakoor, N. and Michalska, M. and Harris, C. A. and Block, J. A.}, citeulike-article-id = {3022000}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/S0140-6736(02)07714-0}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/11867114}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=11867114}, day = {16}, doi = {10.1016/S0140-6736(02)07714-0}, issn = {0140-6736}, journal = {Lancet}, keywords = {anti-tnf}, month = {February}, number = {9306}, pages = {579--580}, posted-at = {2008-07-20 04:55:13}, priority = {2}, title = {Drug-induced systemic lupus erythematosus associated with etanercept therapy.}, url = {http://dx.doi.org/10.1016/S0140-6736(02)07714-0}, volume = {359}, year = {2002} }

TY - JOUR ID - citeulike:3022000 L3 - citeulike-article-id:3022000 N2 - Specific antagonists of tumour necrosis factor (TNF)-alpha have rapidly gained popularity for the treatment of rheumatoid arthritis. The monoclonal antibody against TNF-alpha, infliximab, has been associated with induction of systemic lupus erythematosus (SLE); however, there have been no published reports of drug-induced SLE associated with the soluble TNF-alpha receptor etanercept. We describe four female patients who developed signs and symptoms of SLE during treatment with etanercept; in two SLE was unambiguous. On diagnosis of SLE, etanercept was discontinued and the SLE-related symptoms promptly resolved. Etanercept should be considered in the list of agents associated with drug-induced SLE. IS - 9306 JF - Lancet SN - 0140-6736 EP - 580 TI - Drug-induced systemic lupus erythematosus associated with etanercept therapy. VL - 359 SP - 579 KW - anti-tnf AU - Shakoor, N AU - Michalska, M AU - Harris, CA AU - Block, JA PY - 2002/02/16/ UR - http://dx.doi.org/10.1016/S0140-6736(02)07714-0 ER -